ATE349447T1 - Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren - Google Patents

Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren

Info

Publication number
ATE349447T1
ATE349447T1 AT00972755T AT00972755T ATE349447T1 AT E349447 T1 ATE349447 T1 AT E349447T1 AT 00972755 T AT00972755 T AT 00972755T AT 00972755 T AT00972755 T AT 00972755T AT E349447 T1 ATE349447 T1 AT E349447T1
Authority
AT
Austria
Prior art keywords
alkylamino
protein kinase
kinase inhibitors
substituted bicyclic
bicyclic heterocycles
Prior art date
Application number
AT00972755T
Other languages
English (en)
Inventor
James Patrick Dunn
David Michael Goldstein
William Harris
Ian Edward David Smith
Teresa Rosanne Welch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE349447T1 publication Critical patent/ATE349447T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00972755T 1999-10-21 2000-10-13 Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren ATE349447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16080499P 1999-10-21 1999-10-21
US21371800P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
ATE349447T1 true ATE349447T1 (de) 2007-01-15

Family

ID=26857242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00972755T ATE349447T1 (de) 1999-10-21 2000-10-13 Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren

Country Status (25)

Country Link
US (1) US6642241B1 (de)
EP (1) EP1226144B1 (de)
KR (1) KR100537241B1 (de)
CN (1) CN1156477C (de)
AR (1) AR026187A1 (de)
AT (1) ATE349447T1 (de)
AU (1) AU776695B2 (de)
BR (1) BR0014973A (de)
CA (1) CA2388140C (de)
CO (1) CO5251408A1 (de)
CZ (1) CZ20021743A3 (de)
DE (1) DE60032623T2 (de)
ES (1) ES2277858T3 (de)
HK (1) HK1051040A1 (de)
HR (1) HRP20020327A2 (de)
HU (1) HUP0203477A3 (de)
IL (1) IL149230A0 (de)
MA (1) MA26836A1 (de)
MX (1) MXPA02003841A (de)
NO (1) NO20021783D0 (de)
PE (1) PE20010760A1 (de)
PL (1) PL357494A1 (de)
TR (1) TR200201058T2 (de)
WO (1) WO2001029041A1 (de)
YU (1) YU29202A (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ID27589A (id) 1998-05-26 2001-04-12 Warner Lambert Comapny Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular
CN1646131A (zh) * 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 新化合物
EP1707205A2 (de) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
KR100793688B1 (ko) * 2002-08-06 2008-01-10 에프. 호프만-라 로슈 아게 Ｐ-38 미토겐 활성 단백질 키나제 억제제로서6-알콕시-피리도-피리미딘
JP4252534B2 (ja) 2002-08-06 2009-04-08 エフ．ホフマン−ラ ロシュ アーゲー ｐ−３８ＭＡＰキナーゼインヒビターとしての６−アルコキシ−ピリド−ピリミジン類
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
BRPI0409366A (pt) * 2003-04-10 2006-04-25 Hoffmann La Roche compostos de pirimido
US20080131370A1 (en) * 2004-04-27 2008-06-05 Takeda Pharmaceutical Company Limited Screening Method
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1789416B1 (de) 2004-08-31 2009-03-11 F. Hoffmann-la Roche AG Amidderivate von 3-phenyldihydropyrimido[4,5-d]pyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
AU2005279337A1 (en) 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US8058283B2 (en) 2006-01-31 2011-11-15 Hoffmann-La Roche Inc. 7H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
EP2108641A1 (de) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SG10201610416TA (en) 2012-06-13 2017-01-27 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EA036160B1 (ru) 2013-03-15 2020-10-08 Селджен Кар Ллс Гетероарильные соединения и их применение
EP3943087A1 (de) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroarylverbindungen und verwendungen davon
HUE036571T2 (hu) 2013-04-19 2018-07-30 Incyte Holdings Corp Biciklusos heterociklusok mint FGFR inhibitorok
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3259269B9 (de) 2015-02-20 2020-03-04 Incyte Corporation Bizyklische heterozyklen als fgfr inhibitoren
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
KR100378937B1 (ko) * 1997-10-20 2003-05-09 에프. 호프만-라 로슈 아게 바이사이클릭 키나아제 억제제
ID27589A (id) * 1998-05-26 2001-04-12 Warner Lambert Comapny Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular
PT1123295E (pt) * 1998-10-23 2005-01-31 Hoffmann La Roche Heterociclos de azoto biciclicos

Also Published As

Publication number Publication date
DE60032623D1 (de) 2007-02-08
AR026187A1 (es) 2003-01-29
EP1226144B1 (de) 2006-12-27
DE60032623T2 (de) 2007-10-11
KR20020039375A (ko) 2002-05-25
JP4028236B2 (ja) 2007-12-26
AU1137501A (en) 2001-04-30
NO20021783L (no) 2002-04-16
WO2001029041A1 (en) 2001-04-26
HK1051040A1 (en) 2003-07-18
CZ20021743A3 (cs) 2002-08-14
PE20010760A1 (es) 2001-07-21
MXPA02003841A (es) 2002-09-30
BR0014973A (pt) 2002-07-16
ES2277858T3 (es) 2007-08-01
IL149230A0 (en) 2002-11-10
HRP20020327A2 (en) 2004-02-29
TR200201058T2 (tr) 2002-07-22
JP2003512377A (ja) 2003-04-02
EP1226144A1 (de) 2002-07-31
AU776695B2 (en) 2004-09-16
US6642241B1 (en) 2003-11-04
YU29202A (sh) 2004-12-31
CN1382142A (zh) 2002-11-27
CO5251408A1 (es) 2003-02-28
CA2388140C (en) 2008-09-02
PL357494A1 (en) 2004-07-26
MA26836A1 (fr) 2004-12-20
HUP0203477A3 (en) 2004-12-28
NO20021783D0 (no) 2002-04-16
CA2388140A1 (en) 2001-04-26
HUP0203477A2 (hu) 2003-01-28
KR100537241B1 (ko) 2005-12-19
CN1156477C (zh) 2004-07-07

Similar Documents

Publication Publication Date Title
ATE349447T1 (de) Alkylamino-substituierte bicyclische heterocyclen als p38 protein kinase inhibitoren
DE69720522D1 (de) Substituierte stickstoff enthaltende heterocyclen als p38 protein kinase inhibitoren
ATE270670T1 (de) Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
NO20021781D0 (no) Heteroalkylamino-substituerte bicykliske nitrogenheterocykler som inhibitorer for P38-proteinkinase
DE60128709D1 (de) Triazol-verbindungen als protein-kinase-inhibitoren
DE60119776D1 (de) Pyrazolverbindungen als protein-kinase-inhibitoren
DE69724789D1 (de) Bicyclische heteroaromatic verbindungen als protein tyrosin kinase inhibitoren
ATE430149T1 (de) Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
DE69718472D1 (de) Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
ATE214381T1 (de) Thiazole derivate als protein kinase c inhibitoren
ZA200202540B (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties